Heterobifunctional Compounds for Selective BRD4 Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current heterobifunctional compounds, such as PROTACs, face challenges in selectively degrading target proteins while sparing homologous proteins, due to unpredictable selectivity and binding profiles, which limits their therapeutic efficacy in diseases mediated by specific protein dysfunction.
Innovation Solution
Development of heterobifunctional compounds represented by Formula (I), which include a targeting ligand that binds bromodomain proteins like BRD4 with high affinity, enabling selective ubiquitin-mediated degradation of BRD4 while sparing BRD2 and BRD3, through specific interactions with an E3 ubiquitin ligase, ensuring selective protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heterobifunctional compounds (PROTACs) are designed to recruit E3 ubiquitin ligase and target protein into close proximity for ubiquitination, then targeted protein degradation is achieved, but selectivity for target protein over homologous proteins becomes unpredictable
Solution Approach 1:
The patent applies local quality by modifying specific regions of the PROTAC molecule - particularly the target-binding moiety and linker region - to enhance selectivity for BRD4 over homologous BET proteins. The heterobifunctional compound structure allows different regions to have specialized functions: the VHL-binding domain recruits the E3 ligase, the linker controls spatial arrangement, and the target-binding domain provides selective recognition, with each region optimized locally to achieve overall molecular selectivity.
2Productivity
If PROTACs use common E3 ligase binding scaffolds like thalidomide analogs or VHL ligands, then E3 ubiquitin ligase recruitment is achieved, but binding profile complexity increases and may cause off-target effects on homologous proteins
Solution Approach 1:
The patent employs asymmetry in the heterobifunctional compound design where the two ends of the molecule have distinct, non-equivalent structures: one end binds VHL with specific geometry while the other binds BRD4 with complementary specificity. This asymmetric architecture ensures that the compound engages BRD4-VHL in a specific orientation that favors productive ternary complex formation while minimizing interactions with homologous BET proteins that have different binding pocket geometries.
3Adaptability or versatility
If the target-moiety binds homologous proteins with similar affinity, then broad target coverage is achieved, but selective degradation of the specific target protein cannot be realized
Solution Approach 1:
The patent utilizes parameter changes by systematically varying key molecular parameters including linker length (affecting spatial distance between binding sites), linker flexibility (affecting conformational entropy), and target-moiety chemical structure (affecting binding affinity and specificity). These parameter optimizations create a molecular geometry that fits the BRD4-VHL interface specifically, with the linker acting as a molecular ruler that positions the binding domains at optimal distances for ternary complex formation while excluding homologous proteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds achieve selective degradation of the target protein, BRD4, with minimal degradation of homologous proteins like BRD2 and BRD3, thereby providing a therapeutic approach for diseases mediated by dysfunctional protein activity.
Implementation Method 1
enabling selective ubiquitin-mediated degradation of BRD4 while sparing BRD2 and BRD3, through specific interactions with an E3 ubiquitin ligase
Data Source
AI summary
Disclosed are heterobifunctional compounds that effectuate selective degradation of a target protein, and which include a targeting ligand that binds a target protein and at least one other protein, a ligand that binds an E3 ubiquitin ligase or a component of E3 ubiquitin ligase, and a specificity modulating linker that links the first ligand and the second ligand. Pharmaceutical compositions containing the compounds, and methods of using and making the compounds are also disclosed.